Genetic alterations affect everolimus benefit in breast cancer The Oncology Report CHICAGO – The benefit of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer appears to be greater for women who have little or no genetic alteration in this cancer's most commonly altered molecular signaling pathways, ... |
